中药外用治疗卡培他滨所致手足综合征的临床观察

被引:0
作者
张明霞
机构
[1] 北京中医药大学
关键词
卡培他滨; 手足综合征; 中医外治;
D O I
暂无
年度学位
2009
学位类型
硕士
导师
摘要
本论文主要包括文献综述和临床研究两个部分。 文献综述的题目是中西医防治卡培他滨所致手足综合征的研究进展,回顾了近年来国内外对卡培他滨所致手足综合征的基础及临床研究进展,主要从临床特点、发生机制、病理特点及中西医防治进展方面进行了论述。综合分析,手足综合征是卡培他滨主要的不良反应之一,严重影响患者的生活质量,甚至可能导致非疾病进展性停药或减量,已受到国内外诸多学者的广泛关注。通过临床观察证明,中药外用在预防和治疗卡培他滨致手足综合征方面有一定的疗效。 临床研究部分,观察了中药外用在治疗卡培他滨致手足综合征方面的疗效。目的:观察卡培他滨化疗的过程中用中药外用以减轻其手足综合征毒副反应的临床疗效。方法:选取卡培他滨化疗后出现手足综合征不良反应者为观察对象,采用自拟中药“通络散”外用(洗/浸),温浴(35~37℃),20min/次,每日早晚各1次,连用7天为1个治疗疗程。疗效评价方法为:自身对照,参照NCI不良反应标准比较治疗前、后的症状、体征,用药后降至0级为治愈,较用药前下降1级及1级以上者为有效,分级无改变者为无效;同时根据WHO疼痛疗效标准结合NRS法双重判定手足综合征引起的疼痛控制情况。结果:35例患者中,33例的不良反应明显减轻,总有效率94.29%(33/35),治愈率45.71%(16/35)。29例手足综合征伴手足痛患者,其中27例疼痛缓解,疼痛总缓解率为93.10%(27/29),完全缓解率为55.17%(16/29),治疗有效病例的起效时间3.00±1.26天,疼痛缓解的起效时间1.93±0.92天。结论:中药外用对卡培他滨化疗所致手足综合征有一定疗效,值得临床进一步研究及推广。
引用
收藏
页数:42
共 22 条
[1]
Topical henna for capecitabine induced hand–foot syndrome [J].
Idris Yucel ;
Gonullu Guzin .
Investigational New Drugs, 2008, 26 :189-192
[2]
Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy [J].
Heo, YS ;
Chang, HM ;
Kim, TW ;
Ryu, MH ;
Ahn, JH ;
Kim, SB ;
Lee, JS ;
Kim, WK ;
Cho, HK ;
Kang, YK .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10) :1166-1172
[3]
Physical activity levels among breast cancer survivors [J].
Irwin, ML ;
Mctiernan, A ;
Bernstein, L ;
Gilliland, FD ;
Baumgartner, R ;
Baumgartner, K ;
Ballard-Barbash, R .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2004, 36 (09) :1484-1491
[4]
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda ? ).[J].Yvonne Lassere;Paulo Hoff.European Journal of Oncology Nursing.2004,
[5]
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda ? ).[J].Hilde Marsé;Eric Van Cutsem;Axel Grothey;Sonia Valverde.European Journal of Oncology Nursing.2004,
[6]
A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy [J].
Chua, DTT ;
Sham, JST ;
Au, GKH .
ORAL ONCOLOGY, 2003, 39 (04) :361-366
[7]
Incidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution Experience.[J].Samer Abushullaih;Everardo D. Saad;Mark Munsell;Paulo M. Hoff.Cancer Investigation.2002, 1
[8]
Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue [J].
Miwa, M ;
Ura, M ;
Nishida, M ;
Sawada, N ;
Ishikawa, T ;
Mori, K ;
Shimma, N ;
Umeda, I ;
Ishitsuka, H .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (08) :1274-1281
[9]
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J].
Ishikawa, T ;
Utoh, M ;
Sawada, N ;
Nishida, M ;
Fukase, Y ;
Sekiguchi, F ;
Ishitsuka, H .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :1091-1097
[10]
PYRIDOXINE THERAPY FOR PALMAR-PLANTAR ERYTHRODYSESTHESIA ASSOCIATED WITH CONTINUOUS 5-FLUOROURACIL INFUSION [J].
FABIAN, CJ ;
MOLINA, R ;
SLAVIK, M ;
DAHLBERG, S ;
GIRI, S ;
STEPHENS, R .
INVESTIGATIONAL NEW DRUGS, 1990, 8 (01) :57-63